Expression of P2Y2 purinoceptors in MCG 101 murine sarcoma cells, and HT-29 human colon carcinoma cells

• We investigated how agonists at purinoceptors may affect tumour cell metabolism. This was investigated in vitro in tumour cell lines by microphysiometry, which method monitors extracellular acidification rate (ECAR), on-line. The cell lines investigated were the murine sarcoma, MCG 101, and the human colon cancer, HT-29. In MCG 101, adenosine-5'-triphosphate (ATP) or uridine-5'-triphosphate (UTP) caused a concentration-dependent increase in ECAR, most likely due to the ligation of P2Y(2) receptors, which response was blocked by suramin. In HT-29, ATP or UTP elicited a concentration-dependent, biphasic change in ECAR (increase/decrease). The pharmacological analysis suggests the involvement of P2Y(2) receptors, although other P2 receptor subtypes cannot be entirely excluded. This biphasic response to UTP or ATP was resistant to suramin. The expression of P2Y(2) receptors was demonstrated in both cell lines by immunocytochemistry and Western blot. The current study, thus, shows the functional and morphological expression of a purinoceptor subtype with partly different effects on metabolism in two different tumour cell lines.

Nyckelord

Adenosine Diphosphate/pharmacology

Adenosine Triphosphate/pharmacology

Animals

Antineoplastic Agents/pharmacology

Blotting

Western/methods

Cell Line

Tumor/drug effects

Colonic Neoplasms/pathology

Dose-Response Relationship

Drug

Drug Interactions

*Gene Expression Regulation

Neoplastic

HT29 Cells

Humans

Hydrogen-Ion Concentration/drug effects

Immunohistochemistry/methods

Mice

Receptors

Purinergic P2/genetics/*metabolism

Sarcoma/pathology

Suramin/pharmacology

Time Factors

Uridine Triphosphate/pharmacology

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)